Skip to main content
Not investment advice. Educational platform. See Disclaimer.
NASDAQ: BMRN

BioMarin Pharmaceutical Inc.

Healthcare | Biotechnology

No licensed closing price on file for BMRN. This page shows the company’s SEC filings and filed figures, without a price or any ratio that depends on one.

EPS (TTM)$0.39

BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) is a biotechnology company. Figures from SEC EDGAR; updated 2026-10-20 15:50 UTC.

What BioMarin Pharmaceutical Inc. does

BioMarin Pharmaceutical is a global biotechnology company focused on rare genetic diseases, based in San Rafael, California and founded in 1997. The company markets eight commercial therapies for conditions including achondroplasia, various forms of mucopolysaccharidosis, phenylketonuria, and hemophilia A. BioMarin pursues drug development through internal research programs, partnerships, and acquisitions of external assets.

Summarized from BioMarin Pharmaceutical Inc.’s SEC filings · AI-generated analysis. Not investment advice. May contain errors. · Read the filing ↗

Key facts

Valuation
EPS (TTM)$0.39
Return on equity5.73%
Debt/equity0.66

Revenue, margins & earnings

FY2021: net loss $64M on revenue $1.85B$1.85BFY2021FY2022 Net income: $142MFY2022 Operating costs: $1.94B$2.10BFY2022FY2023 Net income: $168MFY2023 Operating costs: $2.23B$2.42BFY2023FY2024 Net income: $427MFY2024 Taxes & interest: $57MFY2024 Operating costs: $2.37B$2.85BFY2024FY2025 Net income: $349MFY2025 Taxes & interest: $61MFY2025 Operating costs: $2.81B$3.22BFY2025
  • Net income
  • Taxes & interest
  • Operating costs
  • Net loss year
Annual revenue; bands show net, operating margins · Open in Platform →

SEC Filings

SEC EDGAR ↗
Recent Insider Activity (last 90 days)
Source: SEC EDGAR · Filed 2026-10-01
  • 2026-10-01EVP, Chief R&D OfficerTax withholding-4,086$245.2K
  • 2026-09-14DirectorAward6,140—
  • 2026-09-03EVP, Chief Legal OfficerSale-17,557$1.16M
Sign in to see all transactions →
Recent 8-K Events (parsed from SEC filings)All events →
Source: SEC EDGAR 8-K filings · Interpretation: Oxford Ledge parser · Confidence-filtered ≥ 0.50

Company news

View all →

Questions this page answers

What does BioMarin Pharmaceutical Inc. do?

BioMarin Pharmaceutical is a global biotechnology company focused on rare genetic diseases, based in San Rafael, California and founded in 1997.

When did BMRN last file with the SEC?

BioMarin Pharmaceutical Inc.'s most recent SEC filing on record is a 8-K filed 2026-06-04. All filings link to their SEC EDGAR originals above.

Where does this data come from?

SEC EDGAR filings, with the company profile (sector, industry, exchange) from public data providers, fetched 2026-10-20 15:50 UTC. This page is also available as JSON at /api/data?ticker=BMRN and is emitted with FAQPage structured data for machine reading.

For you

Charts, 10-year financials, peer comparison, screening and portfolio tracking for BMRN and 5,000+ tickers.

Create a free account — keep BMRN
For your agent
GET /api/data?ticker=BMRN

This page as JSON via rel="alternate" · REST API docs · MCP server (60 tools) · llms.txt